Drug
Deutarserine clinical trials
Also written CTP-692.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Development codes
- CTP-692
- 4
Studies by the year they started
4 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses deutarserine is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With SchizophreniaCompletedPhase 2Concert PharmaceuticalsNCT04158687Written as CTP-692
- Study to Assess the Safety and Pharmacokinetic (PK) of CTP-692 in Healthy VolunteersCompletedPhase 1Concert PharmaceuticalsNCT03830463Written as CTP-692
- Multiple Ascending Dose Study of CTP-692 in Healthy VolunteersCompletedPhase 1Concert PharmaceuticalsNCT03880253Written as CTP-692
- A Study to Compare the Safety, Tolerability, and Pharmacokinetics of CTP-692 Versus D-serine in Healthy VolunteersCompletedPhase 1Concert PharmaceuticalsNCT03778320Written as CTP-692
Codes
What other systems call deutarserine · ClinicalTrials.gg INT017471
- UNII (FDA) OD54L0MH86DEUTARSERINEOne source FDA
- NCI Thesaurus C177091DeutarserineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OD54L0MH86 | DEUTARSERINE | One source FDA |
| NCI Thesaurus | C177091 | Deutarserine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.